期刊
PHARMACEUTICS
卷 14, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14051010
关键词
oral drug products; clinically relevant dissolution specifications; PBBM; product performance; biorelevant dissolution
In 2021, a webinar series organized by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial, regulatory, and academic scientists came together to discuss progress, emerging trends, and areas for collaboration and harmonization in this field.
A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据